|Day Low/High||5.25 / 5.50|
|52 Wk Low/High||5.02 / 11.18|
In trading on Thursday, shares of Merrimack Pharmaceuticals Inc. crossed above their 200 day moving average of $6.12, changing hands as high as $6.73 per share.
No matter who wins the election, Jim Cramer says, there are ways to make money.
Acceptance further validates Merrimack's leadership in development and manufacturing of complex liposomal formulations
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the June 2017 expiration.
Merrimack Pharmaceuticals' (MACK) stock rating was reduced to 'neutral' at JPMorgan earlier today.
The first day of trading in the fourth quarter was rough as stocks declined Monday.
U.S. stocks closed lower on Monday amid lower construction spending, mostly strong auto sales, and better-than-expected manufacturing data. Crude oil increased and utilities lagged.
U.S. stocks pare losses in afternoon trading Monday as investors grapple with mixed data, but oil prices increase.
Merrimack Pharmaceuticals (MACK) announced today the resignation of CEO Robert Mulroy as well as a 22% reduction in its workforce.
- Final results of NAPOLI-1 study will be presented in a poster discussion session
Thermo Fisher is looking bullish, while Blue Buffalo goes the other way.
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the November 18th expiration.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
New drugs give small-cap companies opportunity to expand markets and revenues.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.
Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a strong on high relative volume candidate
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the August 19th expiration.
Oral presentation on Phase 3 NAPOLI-1 data will highlight the effects of the ONIVYDE® (irinotecan liposome injection) regimen on quality of life for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy